HOPIN
23.3.2021 12:32:06 CET | Business Wire | Press release
Hopin , the leading virtual experience platform, announced today that it has acquired video hosting provider Streamable and video technology company Jamm . The technology from both companies will be integrated into Hopin’s current product offering and become the basis for the development of future video products and features. The acquisitions solidify Hopin’s focus to holistically improve its professional-grade video capabilities for organizers that host events on Hopin and to build out its suite of new, video-centric products.
“As the world reopens, high-quality virtual experiences will continue to be critical. Video will be the primary communication channel for businesses, creators and organizations to share experiences virtually, so these acquisitions are a natural next step,” said Johnny Boufarhat, founder and CEO of Hopin. “The technology and resources from Jamm and Streamable will become foundational components to future products and the entire Hopin video experience — from production and video quality to how our customers can collaborate and distribute content.”
Streamable is a popular video hosting site founded by Armen Petrosian in 2014. Petrosian has grown Streamable for the past seven years to become a leading video hosting service that has 75,000 new video uploads per day and over 5,000 paying customers in more than 100 countries. Petrosian will continue to lead Streamable’s business and help build new products at Hopin.
“At Streamable, we’ve always wanted to build products that are simple and easy to use for everyone and we recognized that Hopin’s goal to bring accessibility to events and meetings dovetailed nicely with our own goals,” said Armen Petrosian, founder and CEO of Streamable. “The first priority for Streamable will be to invest in our product suite and ultimately integrate the Streamable platform into Hopin’s future suite of products.”
Jamm was founded in 2019 by Badri Rajasekar to create a lightweight way for users to collaborate over video. Rajasekar is an expert in video technology and was previously CTO of the real-time communication API platform TokBox prior to Jamm. TokBox was acquired by Telefonica in 2012 and subsequently spun out to Vonage in 2018. Jamm hosts a number of customers including Swoop, SignEasy, Deepsource, Stackery and others across a range of industry verticals such as fintech, gaming, education and more. Rajasekar will play a key role in helping develop new features and products in-house at Hopin.
“Since I founded Jamm in 2019, we’ve seen growing interest as more businesses pursue a remote-work strategy. I’ve witnessed firsthand how productive remote teams can become when they have a video solution that’s lightweight and collaborative,” said Jamm founder and CEO Badri Rajasekar. “I’m excited to bring my expertise to Hopin and build upon the great products Johnny has already developed, to make virtual experiences even easier for Hopin customers.”
Hopin continues to see impressive demand for its products and services. In a little over a year, Hopin has grown to millions of users and more than 90,000 organizers hosting events. The two acquisitions are a continuation of Hopin’s rapid growth, as it looks to its future product roadmap to drive and meet the demand of current and future customers. Hopin recently acquired mobile app development company Topi and video streaming company StreamYard, adding StreamYard’s 3.6 million video content creators to its base. Hopin has also raised $570M to-date, with its most recent raise a $400M Series C earlier this month, co-led by Andreessen Horowitz and General Catalyst.
About Hopin
Founded in 2019, Hopin enables brands and communities to create all-in-one live video experiences for their audiences. Through its platforms, attendees can learn, interact, and connect with people from anywhere in the world. With Hopin, you can create live virtual and hybrid events that are interactive and immersive. Hopin acquired StreamYard, a leading video streaming studio, in 2020. Hopin is a remote-first company headquartered in London, with employees in 42 countries. Learn more at hopin.com.
About Streamable
Streamable is an internet video streaming company that powers innovative video experiences for thousands of creators and businesses all around the world. With Streamable, you can upload, crop, trim, embed and share videos — all without ever leaving your browser. Whether you’re just getting started or you have advanced video hosting and editing needs, Streamable is perfect for you. Get started today at https://streamable.com .
About Jamm
Jamm is a virtual workplace application that enables lightweight voice and video collaboration for remote teams. Jamm aims to unlock more spontaneous connections and short bursty conversations in the workplace. With powerful collaboration features like screen-sharing, white-boarding, recorded video stories and more — unlock your team’s full potential with Jamm. Try it out now at https://jamm.app .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005439/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom